SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla jumps after filing ANDA for generic version of GSK’s Advair Diskus

18 May 2020 Evaluate
Cipla is currently trading at Rs. 585.95, up by 15.75 points or 2.76% from its previous closing of Rs. 570.20 on the BSE.

The scrip opened at Rs. 570.45 and has touched a high and low of Rs. 589.00 and Rs. 570.45 respectively. So far 171580 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 632.05 on 27-Apr-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 603.50 and Rs. 565.90 respectively. The current market cap of the company is Rs. 47314.15 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.

Cipla has submitted an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the United States Food and Drug Administration (USFDA). The company had recently announced the successful completion of its Phase-3 clinical end-point study for the product in the first attempt.

The product is the generic version of GSK’s Advair Diskus. According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of approximately $2.9bn for the 12-month period ending March 2020. It is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older. It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1363.45 29.90 (2.24%)
06-May-2026 13:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1852.65
Dr. Reddys Lab 1311.95
Cipla 1363.45
Zydus Lifesciences 933.80
Lupin 2430.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×